Modulation of eif4e-bp2

Abstract

Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.

1 - 40 . (canceled) 
     
     
         41 . A modified antisense compound 13 to 80 nucleobases in length targeted to a nucleic acid molecule encoding eIF4E-BP2 (SEQ ID NO:4), wherein said compound has at least an 8-nucleobase portion complementary within nucleotides 544-940, 420-439, 493-512, 1962-1981, 501-520, 8892-8911, 11559-11578, 11918-11937, 17941-17960, 146-165, 332-351, 372-391, 474-493, 1868-1887, 1900-1919, 2218-2237, 2223-2242, 2377-2396, 2382-2401, 2449-2468, 2471-2490, 2536-2555, 2578-2597, 2632-2651, 2088-2107, or 697-716 of SEQ ID NO:4 encoding eIF4E-BP2, and wherein said compound inhibits the expression of eIF4E-BP2 mRNA. 
     
     
         42 . The antisense compound of  claim 41  which is 13 to 50 nucleobases in length. 
     
     
         43 . The antisense compound of  claim 41  which is 15 to 30 nucleobases in length. 
     
     
         44 . The antisense compound of  claim 41  comprising an oligonucleotide. 
     
     
         45 . The antisense compound of  claim 41  comprising a DNA oligonucleotide. 
     
     
         46 . The antisense compound of  claim 41  comprising an RNA oligonucleotide. 
     
     
         47 . The antisense compound of  claim 41  which is a double-stranded oligonucleotide. 
     
     
         48 . The antisense compound of  claim 41  which is a single-stranded oligonucleotide. 
     
     
         49 . The antisense compound of  claim 41  comprising a chimeric oligonucleotide. 
     
     
         50 . The antisense compound of  claim 41  wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex. 
     
     
         51 . The antisense compound of  claim 41  having at least one modified internucleoside linkage, sugar moiety, or nucleobase. 
     
     
         52 . The antisense compound of  claim 41  having at least one 2′-O-methoxyethyl sugar moiety. 
     
     
         53 . The antisense compound of  claim 41  having at least one phosphorothioate internucleoside linkage. 
     
     
         54 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 420-439 of SEQ ID NO:4 encoding eIF4E-BP2. 
     
     
         55 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 501-520 of SEQ ID NO:4 encoding eIF4E-BP2. 
     
     
         56 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 332-351 of SEQ ID NO:4 encoding eIF4E-BP2. 
     
     
         57 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 829-848 of SEQ ID NO:4 encoding eIF4E-BP2. 
     
     
         58 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 851-870 of SEQ ID NO:4 encoding eIF4E-BP2. 
     
     
         59 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 868-887 of SEQ ID NO:4 encoding eIF4E-BP2. 
     
     
         60 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 921-940 of SEQ ID NO:4 encoding eIF4E-BP2. 
     
     
         61 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 2377-2396 of SEQ ID NO:4 encoding eIF4E-BP2. 
     
     
         62 . The antisense compound of  claim 41 , wherein said antisense compound has at least an 8-nucleobase portion complementary within nucleotides 2578-2597 of SEQ ID NO:4 encoding eIF4E-BP2.